Number of times cited according to CrossRef:

Fabrizio Schifano, Caroline Zangani, Stefania Chiappini, Amira Guirguis, Stefania Bonaccorso, John M. Corkery, Substance-Use Disorders and Violence, Violence and Mental Disorders, 10.1007/978-3-030-33188-7_6, (95-114),

Marco Colizzi, Sagnik Bhattacharyya, Is there sufficient evidence that cannabis use is a risk factor for psychosis?, Risk Factors for Psychosis, 10.1016/B978-0-12-813201-2.00016-8, (305-331),

Elena Deligianni, Omari J. Daniel, John M. Corkery, Fabrizio Schifano, Lisa A. Lione, Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances, British Journal of Clinical Pharmacology, 10.1111/bcp.14123, 86, 3, (505-516),

GÜNEY Erengül, Alnıak İzgi, Erkıran Murat, PREDICTING FACTORS FOR NON-SUICIDAL SELF-INJURY IN PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS AND THE ROLE OF SUBSTANCE USE, Asian Journal of Psychiatry, 10.1016/j.ajp.2020.102068, (102068),

Claire L. Gibson, Anahita Bassir Nia, Sharron A. Spriggs, Daniel DeFrancisco, Amy Swift, Charles Perkel, Xiaobo Zhong, Madhu Mazumdar, Nicolas Fernandez, Manishkumar Patel, Seunghee Kim-Schulze, Yasmin L. Hurd, Cannabinoid use in psychotic patients impacts inflammatory levels and their association with psychosis severity, Psychiatry Research, 10.1016/j.psychres.2020.113380, (113380),

Sulaf Assi, Danielle Marshall, Francesco Saverio Bersani, Ornella Corazza, Uses, Effects and Toxicity of Synthetic Cannabinoids from the Perspective of People with Lived Experiences, Journal of Psychoactive Drugs, 10.1080/02791072.2020.1723748, (1-11),

Koby Cohen, Shiri Rosenzweig, Paola Rosca, Albert Pinhasov, Abraham Weizman, Aviv Weinstein, Personality Traits and Psychotic Proneness Among Chronic Synthetic Cannabinoid Users, Frontiers in Psychiatry, 10.3389/fpsyt.2020.00355, 11,

Paul Gray, Rob Ralphs, Lisa Williams, The use of synthetic cannabinoid receptor agonists (SCRAs) within the homeless population: motivations, harms and the implications for developing an appropriate response, Addiction Research & Theory, 10.1080/16066359.2020.1730820, (1-10),

Marco Colizzi, Mirella Ruggeri, Sagnik Bhattacharyya, Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition, Frontiers in Psychology, 10.3389/fpsyg.2020.00833, 11,

Armağan ARAL, Bahattin AVCI, Miraç Barış USTA, Sentetik Kannabinoidlerin Nöropsikiyatrik Etkileri, Arşiv Kaynak Tarama Dergisi, 10.17827/aktd.524931, 29, 1, (29-36),

Dino Luethi, Matthias E. Liechti, Designer drugs: mechanism of action and adverse effects, Archives of Toxicology, 10.1007/s00204-020-02693-7,

Flavia Napoletano, Fabrizio Schifano, John Martin Corkery, Amira Guirguis, Davide Arillotta, Caroline Zangani, Alessandro Vento, The Psychonauts’ World of Cognitive Enhancers, Frontiers in Psychiatry, 10.3389/fpsyt.2020.546796, 11,

Miriam Schneider, Chris Maria Friemel, Rupert von Keller, Kristina Adorjan, Udo Bonnet, Alkomiet Hasan, Derik Hermann, Joseph Kambeitz, Dagmar Koethe, Ludwig Kraus, F. Markus Leweke, Beat Lutz, Liane Paul, Oliver Pogarell, Ulrich Preuss, Michael Schäfer, Sophia Schmieder, Roland Simon, Martin Storr, Eva Hoch, Cannabiskonsum zum Freizeitgebrauch, Cannabis: Potenzial und Risiko, 10.1007/978-3-662-57291-7, (65-264),

Andrey Viktorovich Antsyborov, Irina Vladimirovna Dubatova, New psychoactive substances: psychiatrist's view, Interactive science, 10.21661/r-497066, 6 (40), (57-67),

Laura Orsolini, Stefania Chiappini, Duccio Papanti, Domenico De Berardis, John M. Corkery, Fabrizio Schifano, The Bridge Between Classical and “Synthetic”/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective, Frontiers in Psychiatry, 10.3389/fpsyt.2019.00851, 10,

Nathan T. Pearson, James H. Berry, Cannabis and Psychosis Through the Lens of DSM-5, International Journal of Environmental Research and Public Health, 10.3390/ijerph16214149, 16, 21, (4149),

Lucia Sideli, Harriet Quigley, Caterina La Cascia, Robin M. Murray, Cannabis Use and the Risk of Psychosis and Affective Disorders, Journal of Dual Diagnosis, 10.1080/15504263.2019.1674991, (1-21),

Murat Yalçın, Nazlı Tunalı, Handan Yıldız, Ayşenur Oğuz, Bülent Kadri Gültekin, Sociodemographic and clinical characteristics of synthetic cannabinoid users in a large psychiatric emergency department in Turkey, Journal of Addictive Diseases, 10.1080/10550887.2019.1671146, (1-9),

Laura Orsolini, Stefania Chiappini, John M. Corkery, Amira Guirguis, Duccio Papanti, Fabrizio Schifano, The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review, Expert Review of Neurotherapeutics, 10.1080/14737175.2019.1666712, (1-12),

F. Schifano, F. Napoletano, S. Chiappini, A. Guirguis, J. M. Corkery, S. Bonaccorso, A. Ricciardi, N. Scherbaum, A. Vento, New/emerging psychoactive substances and associated psychopathological consequences, Psychological Medicine, 10.1017/S0033291719001727, (1-13),

Hina Akram, Claire Mokrysz, H Valerie Curran, What are the psychological effects of using synthetic cannabinoids? A systematic review, Journal of Psychopharmacology, 10.1177/0269881119826592, (026988111982659),

Joshua T. Ellsworth, Spice, vulnerability, and victimization: Synthetic cannabinoids and interpersonal crime victimization among homeless adults, Substance Abuse, 10.1080/08897077.2019.1686725, (1-7),

Jasmin Grigg, Victoria Manning, Shalini Arunogiri, Dan I Lubman, Synthetic cannabinoid use disorder: an update for general psychiatrists, Australasian Psychiatry, 10.1177/1039856218822749, (103985621882274),

Kathryn Higgins, Nina O’Neill, Leeanne O’Hara, Julie-Ann Jordan, Mark McCann, Tara O’Neill, Mike Clarke, Tony O’Neill, Anne Campbell, Evidence for public health on novel psychoactive substance use: a mixed-methods study, Public Health Research, 10.3310/phr07140, 7, 14, (1-150),

Slavica Vučinić, Vesna Kilibarda, Snežana Đorđević, Dragana Đorđević, Nataša Perković-Vukčević, Gordana Vuković-Ercegović, Biljana Antonijević, Marijana Ćurčić, Evica Antonijević, Gordana Brajković, Clinical and analytical experience of the National Poison Control Centre with synthetic cannabinoids, Archives of Industrial Hygiene and Toxicology, 10.2478/aiht-2018-69-3096, 69, 2, (178-185),

Bernd Werse, Dirk Egger, Neue psychoaktive Substanzen: Konsummuster, Konsummotive, Nebenwirkungen und problematischer Konsum, Handbuch Psychoaktive Substanzen, 10.1007/978-3-642-55125-3, (217-228),

Nick Meader, Noreen Mdege, Jim McCambridge, The public health evidence-base on novel psychoactive substance use: scoping review with narrative synthesis of selected bodies of evidence, Journal of Public Health, 10.1093/pubmed/fdy016, 40, 3, (e303-e319),

E Roderick, J Penney, T Murrells, P I Dargan, I J Norman, Epidemiology of adolescent substance use in Norfolk schools, QJM: An International Journal of Medicine, 10.1093/qjmed/hcy153, 111, 10, (699-706),

Björn Moosmann, Volker Auwärter, Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten, Handbuch Psychoaktive Substanzen, 10.1007/978-3-642-55125-3, (389-409),

Papanti Duccio, Schifano Fabrizio, Orsolini Laura, Synthetic Cannabinoids and Synthetic Cannabinoid-Induced Psychotic Disorders, The Complex Connection Between Cannabis and Schizophrenia, 10.1016/B978-0-12-804791-0.00009-4, (199-220),

John Lally, ‘Legal highs’ – what's in a name?, BJPsych Bulletin, 10.1192/pb.39.4.206, 39, 4, (206-206),

Koby Cohen, Aviv M. Weinstein, Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective, Frontiers in Public Health, 10.3389/fpubh.2018.00162, 6,

Andrew Parrott, Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs, Brain Sciences, 10.3390/brainsci8030043, 8, 3, (43),

Stefania Bonaccorso, Antonio Metastasio, Angelo Ricciardi, Neil Stewart, Leila Jamal, Naasir-Ud-Dinn Rujully, Christos Theleritis, Stefano Ferracuti, Giuseppe Ducci, Fabrizio Schifano, Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues, Brain Sciences, 10.3390/brainsci8070133, 8, 7, (133),

Adriana Joseph, Helen-Maria Lekas, Marc Manseau, Crystal Lewis, A Polydrug and Psychosocial Profile of Synthetic Cannabinoid Use in a New York City Community Sample, 2016–2017, Substance Use & Misuse, 10.1080/10826084.2018.1517178, (1-6),

Luca Zamengo, Giampietro Frison, Guus Zwitser, Understanding and managing the new psychoactive substances phenomenon: a holistic approach, Journal of Public Health Policy, 10.1057/s41271-018-0156-6,

Libor Uttl, Ewa Szczurowska, Kateřina Hájková, Rachel R. Horsley, Kristýna Štefková, Tomáš Hložek, Klára Šíchová, Marie Balíková, Martin Kuchař, Vincenzo Micale, Tomáš Páleníček, Behavioral and Pharmacokinetic Profile of Indole-Derived Synthetic Cannabinoids JWH-073 and JWH-210 as Compared to the Phytocannabinoid Δ9-THC in Rats, Frontiers in Neuroscience, 10.3389/fnins.2018.00703, 12,

Kirsten Elin Smith, Michele Staton, Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?, Substance Abuse, 10.1080/08897077.2018.1528495, (1-10),

Koby Cohen, Aviv Weinstein, The Effects of Cannabinoids on Executive Functions: Evidence from Cannabis and Synthetic Cannabinoids—A Systematic Review, Brain Sciences, 10.3390/brainsci8030040, 8, 3, (40),

Cristina Miliano, Giulia Margiani, Liana Fattore, Maria De Luca, Sales and Advertising Channels of New Psychoactive Substances (NPS): Internet, Social Networks, and Smartphone Apps, Brain Sciences, 10.3390/brainsci8070123, 8, 7, (123),

Kirsten Elin Smith, Amanda M. Bunting, Michele Staton, Robert Walker, Sara Shalash, Erin Winston, Kevin Pangburn, Examination of Synthetic Cannabinoid and Cathinone Use among a Drug-Using Offender Sample, 2013–2015, Journal of Psychoactive Drugs, 10.1080/02791072.2017.1361560, 49, 5, (436-445),

Nicholas Pintori, Barbara Loi, Maddalena Mereu, Synthetic cannabinoids, Behavioural Pharmacology, 10.1097/FBP.0000000000000323, 28, 6, (409-419),

Rob Ralphs, Lisa Williams, Rebecca Askew, Anna Norton, Adding Spice to the Porridge11‘Porridge’ is British slang for a prison sentence. E.g. ‘Doing his porridge’. The term is most commonly thought to be an allusion to the fact that porridge is, or used to be, a common food in prison. The term is also thought to be a pun on the much older slang word for prison, ‘stir’.: The development of a synthetic cannabinoid market in an English prison, International Journal of Drug Policy, 10.1016/j.drugpo.2016.10.003, 40, (57-69),

Andrew C. Parrott, Amie C. Hayley, Luke A. Downey, Recreational stimulants, herbal, and spice cannabis: The core psychobiological processes that underlie their damaging effects, Human Psychopharmacology: Clinical and Experimental, 10.1002/hup.2594, 32, 3,

Tiziano Acciavatti, Matteo Lupi, Rita Santacroce, Andrea Aguglia, Luigi Attademo, Laura Bandini, Paola Ciambrone, Giulia Lisi, Giovanni Migliarese, Federica Pinna, Diego Quattrone, Michele Ribolsi, Maria Salvina Signorelli, Salvatore Calò, Fabrizio Schifano, Massimo Giannantonio, Giovanni Martinotti, Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter‐observational study, Human Psychopharmacology: Clinical and Experimental, 10.1002/hup.2578, 32, 3,

Colin Davidson, Jolanta Opacka-Juffry, Angel Arevalo-Martin, Daniel Garcia-Ovejero, Eduardo Molina-Holgado, Francisco Molina-Holgado, Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events, Cannabinoid Pharmacology, 10.1016/bs.apha.2017.05.001, (135-168),

Alberto Salomone, Marco Vincenti, Enrico Gerace, Interpretation of NPS results in real hair samples, Toxicologie Analytique et Clinique, 10.1016/j.toxac.2016.12.008, 29, 1, (4-10),

Stella Welter, Caroline Lücke, Alexandra Philomena Lam, Christina Custal, Sebastian Moeller, Peter Sörös, Christiane M. Thiel, Alexandra Philipsen, Helge H.O. Müller, Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study, European Addiction Research, 10.1159/000479554, 23, 4, (182-193),

M.T. Zanda, L. Fattore, Novel Psychoactive Substances, Addictive Substances and Neurological Disease, 10.1016/B978-0-12-805373-7.00029-3, (341-353),

Fabrizio Schifano, Laura Orsolini, Duccio Papanti, John Corkery, NPS: Medical Consequences Associated with Their Intake, Neuropharmacology of New Psychoactive Substances (NPS), 10.1007/7854_2016_15, (351-380),

Björn Moosmann, Volker Auwärter, Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten, Handbuch Psychoaktive Substanzen, 10.1007/978-3-642-55214-4, (1-27),

Shaina A. Freund, Adrian S. Banning, Synthetic cannabinoids, Journal of the American Academy of Physician Assistants, 10.1097/01.JAA.0000525914.28344.e2, 30, 11, (1-4),

Laura Orsolini, Gabriele Duccio Papanti, Domenico De Berardis, Amira Guirguis, John Martin Corkery, Fabrizio Schifano, The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review, Frontiers in Psychiatry, 10.3389/fpsyt.2017.00240, 8,

Noreen D Mdege, Nick Meader, Charlie Lloyd, Steve Parrott, Jim McCambridge, The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations, Public Health Research, 10.3310/phr05040, 5, 4, (1-138),

Kirstin J. Lauritsen, Harold Rosenberg, Jon E. Sprague, University students’ attributions for abstinence from synthetic cannabinoids and synthetic cathinones, The American Journal of Drug and Alcohol Abuse, 10.1080/00952990.2017.1289214, (1-9),

Rebecca C. Hanna, Jessica M. Perez, Subroto Ghose, Cannabis and development of dual diagnoses: A literature review, The American Journal of Drug and Alcohol Abuse, 10.1080/00952990.2016.1213273, 43, 4, (442-455),

Bryan Lee Miller, John M. Stogner, J. Mitchell Miller, M. Isabel Fernandez, The Arrest and Synthetic Novel Psychoactive Drug Relationship, Journal of Drug Issues, 10.1177/0022042616678611, 47, 1, (91-103),

James G. Phillips, Rowan P. Ogeil, Cannabis, alcohol use, psychological distress, and decision-making style, Journal of Clinical and Experimental Neuropsychology, 10.1080/13803395.2016.1255311, 39, 7, (670-681),

Cornelius Hess, Jacqueline Murach, Lynn Krueger, Lisa Scharrenbroch, Michael Unger, Burkhard Madea, Konrad Sydow, Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography‐tandem mass spectrometry and retrospective application to real forensic samples, Drug Testing and Analysis, 10.1002/dta.2030, 9, 5, (721-733),

Adriana M. Joseph, Marc W. Manseau, Monique Lalane, Amit Rajparia, Crystal Fuller Lewis, Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting, The American Journal of Drug and Alcohol Abuse, 10.1080/00952990.2016.1240799, 43, 1, (117-122),

Maria Antonietta De Luca, M. Paola Castelli, Barbara Loi, Alessandra Porcu, Mariella Martorelli, Cristina Miliano, Kathryn Kellett, Colin Davidson, Jacqueline L. Stair, Fabrizio Schifano, Gaetano Di Chiara, Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135, Neuropharmacology, 10.1016/j.neuropharm.2015.11.017, 105, (630-638),

Fabrizio Schifano, G. Duccio Papanti, Laura Orsolini, John M. Corkery, Novel psychoactive substances: the pharmacology of stimulants and hallucinogens, Expert Review of Clinical Pharmacology, 10.1586/17512433.2016.1167597, 9, 7, (943-954),

Loretta T Ford, Jonathan D Berg, 1-Adamantylamine a simple urine marker for screening for third generation adamantyl-type synthetic cannabinoids by ultra-performance liquid chromatography tandem mass spectrometry, Annals of Clinical Biochemistry, 10.1177/0004563216628892, 53, 6, (640-646),

Anahita Bassir Nia, Benjamin Medrano, Charles Perkel, Igor Galynker, Yasmin L Hurd, Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis, Journal of Psychopharmacology, 10.1177/0269881116658990, 30, 12, (1321-1330),

Colin Davidson, Fabrizio Schifano, The potential utility of some legal highs in CNS disorders, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 10.1016/j.pnpbp.2015.07.010, 64, (267-274),

Jack L Stanley, Daniel V Mogford, Rebecca J Lawrence, Stephen M Lawrie, Use of novel psychoactive substances by inpatients on general adult psychiatric wards, BMJ Open, 10.1136/bmjopen-2015-009430, 6, 5, (e009430),

Odd Martin Vallersnes, Alison M. Dines, David M. Wood, Christopher Yates, Fridtjof Heyerdahl, Knut Erik Hovda, Isabelle Giraudon, Paul I. Dargan, Psychosis associated with acute recreational drug toxicity: a European case series, BMC Psychiatry, 10.1186/s12888-016-1002-7, 16, 1,

Bernd Werse, Dirk Egger, Neue psychoaktive Substanzen: Konsummuster, Konsummotive, Nebenwirkungen und problematischer Konsum, Handbuch Psychoaktive Substanzen, 10.1007/978-3-642-55214-4, (1-16),

Robin M. Murray, Harriet Quigley, Diego Quattrone, Amir Englund, Marta Di Forti, Traditional marijuana, high‐potency cannabis and synthetic cannabinoids: increasing risk for psychosis, World Psychiatry, 10.1002/wps.20341, 15, 3, (195-204),

David M. Wood, Paul I. Dargan, The toxicity of the novel psychoactive substances, Current Practice in Forensic Medicine, 10.1002/9781118456026, (35-46),

Andrea Ossato, Isabella Canazza, Claudio Trapella, Fabrizio Vincenzi, Maria Antonietta De Luca, Claudia Rimondo, Katia Varani, Pier Andrea Borea, Giovanni Serpelloni, Matteo Marti, Effect of JWH-250, JWH-073 and their interaction on “tetrad”, sensorimotor, neurological and neurochemical responses in mice, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 10.1016/j.pnpbp.2016.01.007, 67, (31-50),

Kirstin J. Lauritsen, Harold Rosenberg, Comparison of outcome expectancies for synthetic cannabinoids and botanical marijuana, The American Journal of Drug and Alcohol Abuse, 10.3109/00952990.2015.1135158, 42, 4, (377-384),

Nabi Zorlu, Maria Angelique Di Biase, Çiğdem Çolak Kalaycı, Andrew Zalesky, Başak Bağcı, Nihan Oğuz, Fazıl Gelal, Lütfullah Beşiroğlu, Şeref Gülseren, Aybala Sarıçiçek, Emre Bora, Christos Pantelis, Abnormal white matter integrity in synthetic cannabinoid users, European Neuropsychopharmacology, 10.1016/j.euroneuro.2016.08.015, 26, 11, (1818-1825),

Liana Fattore, Synthetic Cannabinoids—Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis, Biological Psychiatry, 10.1016/j.biopsych.2016.02.001, 79, 7, (539-548),

Kristen Clements-Nolle, Taylor Lensch, Sandra Larson, Wei Yang, Prevalence and Correlates of Any and Frequent Synthetic Cannabinoid Use in a Representative Sample of High School Students, Substance Use & Misuse, 10.3109/10826084.2016.1160121, 51, 9, (1139-1146),

Serdar Nurmedov, Onat Yilmaz, Asli E. Darcin, Onur C. Noyan, Nesrin Dilbaz, Frequency of Synthetic Cannabinoid Use and Its Relationship with Socio-Demographic Characteristics and Treatment Outcomes in Alcohol-and Substance-Dependent Inpatients: A retrospective study, Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, 10.5455/bcp.20150207072424, 25, 4, (348-354),

Cristina Miliano, Giovanni Serpelloni, Claudia Rimondo, Maddalena Mereu, Matteo Marti, Maria Antonietta De Luca, Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants, Frontiers in Neuroscience, 10.3389/fnins.2016.00153, 10,

Alberto Salomone, Giulia Gazzilli, Daniele Di Corcia, Enrico Gerace, Marco Vincenti, Determination of cathinones and other stimulant, psychedelic, and dissociative designer drugs in real hair samples, Analytical and Bioanalytical Chemistry, 10.1007/s00216-015-9247-4, 408, 8, (2035-2042),

Robert J. Tait, David Caldicott, David Mountain, Simon L. Hill, Simon Lenton, A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment, Clinical Toxicology, 10.3109/15563650.2015.1110590, 54, 1, (1-13),

Travis W. Grim, Jason M. Wiebelhaus, Anthony J. Morales, S. Stevens Negus, Aron H. Lichtman, Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice, Drug and Alcohol Dependence, 10.1016/j.drugalcdep.2015.01.022, 150, (31-37),

Kathleen S Bonnici, Paul I Dargan, David M Wood, Novel psychoactive substances or ‘legal highs', British Journal of Hospital Medicine, 10.12968/hmed.2015.76.9.C130, 76, 9, (C130-C134),

David Baumeister, Luis M. Tojo, Derek K. Tracy, Legal highs: staying on top of the flood of novel psychoactive substances, Therapeutic Advances in Psychopharmacology, 10.1177/2045125314559539, 5, 2, (97-132),

Fabrizio Schifano, Novel psychoactive substances (NPS): clinical and pharmacological issues, Drugs and Alcohol Today, 10.1108/DAT-10-2014-0035, 15, 1, (21-27),

Oscar D'Agnone, What have we learned and what can we do about NPS?, Drugs and Alcohol Today, 10.1108/DAT-12-2014-0041, 15, 1, (28-37),

Fabrizio Schifano, Laura Orsolini, G. Duccio Papanti, John M. Corkery, Novel psychoactive substances of interest for psychiatry, World Psychiatry, 10.1002/wps.20174, 14, 1, (15-26),

Novel psychoactive substances: second and third international conferences, Human Psychopharmacology: Clinical and Experimental, 10.1002/hup.2501, 30, 4, (209-212),

Giuseppe Valeriani, Ornella Corazza, Francesco Saverio Bersani, Claudia Melcore, Antonio Metastasio, Giuseppe Bersani, Fabrizio Schifano, Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance‐related psychotic symptoms, Human Psychopharmacology: Clinical and Experimental, 10.1002/hup.2431, 30, 4, (249-254),

Rita Santacroce, Ornella Corazza, Giovanni Martinotti, Francesco Saverio Bersani, Giuseppe Valeriani, Massimo Di Giannantonio, Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products, Human Psychopharmacology: Clinical and Experimental, 10.1002/hup.2410, 30, 4, (265-271),

Sharon S. Kelley, James Godin, John Christie, “Street” and Prescription Drug Abuse, Hamilton & Hardy's Industrial Toxicology, 10.1002/9781118834015, (1267-1282),

Shane M. Wilkinson, Samuel D. Banister, Michael Kassiou, Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids, Australian Journal of Chemistry, 10.1071/CH14198, 68, 1, (4),

M.A. De Luca, Z. Bimpisidis, M. Melis, M. Marti, P. Caboni, V. Valentini, G. Margiani, N. Pintori, I. Polis, G. Marsicano, L.H. Parsons, G. Di Chiara, Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid, Neuropharmacology, 10.1016/j.neuropharm.2015.08.041, 99, (705-714),

Jan van Amsterdam, Tibor Brunt, Wim van den Brink, The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects, Journal of Psychopharmacology, 10.1177/0269881114565142, 29, 3, (254-263),

Jean-Claude Alvarez, Elise Pape, Stanislas Grassin-Delyle, Adeline Knapp, Cannabinoïdes de synthèse : aspects pharmacologiques, Toxicologie Analytique et Clinique, 10.1016/j.toxac.2014.09.054, 27, 1, (23-32),

Alberto Salomone, Detection of New Psychoactive Substances, Hair Analysis in Clinical and Forensic Toxicology, 10.1016/B978-0-12-801700-5.00011-X, (301-336),

Marisol S. Castaneto, Ariane Wohlfarth, Nathalie A. Desrosiers, Rebecca L. Hartman, David A. Gorelick, Marilyn A. Huestis, Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices, Drug Metabolism Reviews, 10.3109/03602532.2015.1029635, 47, 2, (124-174),

Anne-Laure Pélissier-Alicot, Les cannabinoïdes de synthèse : épidémiologie, modalités de consommations et effets cliniques, Toxicologie Analytique et Clinique, 10.1016/j.toxac.2014.10.002, 27, 1, (33-40),

Jolanta B. Zawilska, “Legal Highs” – An Emerging Epidemic of Novel Psychoactive Substances, The Neuropsychiatric Complications of Stimulant Abuse, 10.1016/bs.irn.2015.02.009, (273-300),

Esther Papaseit, Magí Farré, Fabrizio Schifano, Marta Torrens, Emerging drugs in Europe, Current Opinion in Psychiatry, 10.1097/YCO.0000000000000071, 27, 4, (243-250),

Jane Carlisle Maxwell, Psychoactive substances—Some new, some old: A scan of the situation in the U.S., Drug and Alcohol Dependence, 10.1016/j.drugalcdep.2013.09.011, 134, (71-77),